AUSTIN, Texas and COPENHAGEN, Denmark, Sept. 19 /PRNewswire-FirstCall/ -- Luminex® Corporation (Nasdaq: LMNX - News), a leading multiplex solution developer, and Exiqon A/S, a leading supplier of high-value gene expression analysis products, announced today the signing of an agreement to co-develop and commercialize microRNA products. Exiqon will develop and manufacture microRNA products on behalf of the Luminex Bioscience Group (LBG) based on Luminex’s xMAP® technology and Exiqon’s Locked Nucleic Acid (LNA(TM)) technology. Combining the strengths and unique advantages of both companies’ core technologies will create a line of microRNA products that are comprehensive, highly specific and easy to use.
